...
首页> 外文期刊>Cancer genetics and cytogenetics >Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
【24h】

Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.

机译:在成骨期慢性粒细胞白血病患者中同时发生t(9; 22)(q34; q11.2)和t(16; 16)(p13; q22)。

获取原文
获取原文并翻译 | 示例
           

摘要

Coexistence of two specific chromosomal translocations in the same clone is an infrequent phenomenon and has only rarely been reported in hematological malignancies. We report a combination of t(16;16)(p13;q22), the Philadelphia translocation t(9;22)(q34;q11.2), and deletion of the long arm of chromosome 7 in a patient with chronic myeloid leukemia in blast phase. Monotherapy treatment with imatinib mesylate resulted in the disappearance of the Ph-positive clone, but with persistence of t(16;16) and del(7) in all of the metaphases examined. The case illustrates that, although imatinib mesylate can be an effective treatment in eradication of the BCR-ABL fusion gene cells, the occurrence of additional specific abnormalities in Philadelphia-positive leukemias may pose a significant therapeutic challenge.
机译:同一克隆中两种特定染色体易位并存是一种罕见现象,在血液系统恶性肿瘤中很少报道。我们报告了t(16; 16)(p13; q22),费城易位t(9; 22)(q34; q11.2)和慢性粒细胞白血病患者中7号染色体长臂的缺失的组合在爆炸阶段。甲磺酸伊马替尼的单药治疗导致Ph阳性克隆的消失,但在所有检查的中期都持续存在t(16; 16)和del(7)。该病例说明,尽管甲磺酸伊马替尼可以有效根除BCR-ABL融合基因细胞,但在费城阳性白血病中其他特定异常的发生可能构成重大的治疗挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号